Ginkgo Bioworks Holdings, Inc. (DNA)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA). The investigation concerns whether Ginkgo and certain of its officers and/or directors have violated federal securities laws.

 

On October 6, 2021, Scorpion Capital published a report about Ginkgo alleging that it is a “colossal scam,” that its business model is a “shell game,” and that the company is highly dependent on related party transaction revenues. The report also calls the company is a “Frankenstein mash-up of the worst frauds of the last 20 years.” Following this news, Ginkgo stock dropped roughly 20%.  

 

If you are aware of any facts relating to this investigation, or purchased Ginkgo shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.